Andrew J. Fromkin, Director at Immunovant, Inc. (IMVT), sold 24,700 shares at $38.78 ($981K) on 2023-12-01, disclosed to the SEC on 2023-12-05.
Scheduled sale ($981k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.78 | 3,941 | $153K | 15.6% |
| 2 | $38.78 | 3,941 | $153K | 15.6% |
| 3 | $39.81 | 3,636 | $145K | 14.7% |
| 4 | $39.81 | 3,636 | $145K | 14.7% |
| 5 | $40.46 | 4,773 | $193K | 19.7% |
| 6 | $40.46 | 4,773 |
| $193K |
| 19.7% |
| Total | $39.73 avg | 24,700 | $981K | 100% |
| Filing → |
| IMVT | SELL | 2025-03-11 | $286K | — | Filing → |
| IMVT | BUY | 2021-08-11 | $43K | — | Filing → |